Previous 10 | Next 10 |
2023-11-08 15:07:59 ET More on Xencor Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $...
Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH ...
2023-10-25 05:54:08 ET More on MorphoSys MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run MorphoSys: Stable Liquidity Amid Challenging Markets Seeking Alpha’s Quant Rating on MorphoSys Historical earnings data for MorphoSys For furt...
Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin ...
Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administrati...
2023-09-11 08:30:28 ET Crinetics Pharmaceuticals ( CRNX ) +66% climbs as lead asset succeeds in Phase 3 trial for acromegaly. Plus Therapeutics ( PSTV ) +25% Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Preventi...
2023-09-11 08:30:28 ET Crinetics Pharmaceuticals ( CRNX ) +66% climbs as lead asset succeeds in Phase 3 trial for acromegaly. Plus Therapeutics ( PSTV ) +25% Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Preventi...
2023-09-05 10:16:43 ET Summary MorphoSys' Q2 2023 earnings exceeded expectations, with Monjuvi sales reaching $23.6m and an operational loss improvement. The company has a solid cash reserve of approximately EUR680m, providing a cash runway for 1-2 years. The upcoming topline ...
2023-08-18 09:14:52 ET Summary MorphoSys reported a decrease in Q2 2023 total revenues to $58.0M and an operating loss of $55.0M. Cash and financial assets totaled approximately $733 million. Pelabresib, a BET inhibitor, shows promise as a treatment for myelofibrosis. In the MANIF...
2023-08-10 11:40:10 ET MorphoSys AG (MOR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...